Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $104.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 18, 2021

            Details:

            Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (“VEGFR”) 1/2/3. Fruquintinib was approved by the China National Medical Products Administration (“NMPA”) in September 2018 under the brand name Elunate®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fruquintinib

            Therapeutic Area: Oncology Product Name: Elunate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Baring Private Equity Asia

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement April 08, 2021

            Details:

            The agreement will aid in company's business growth as it looks to ramp up its oncology revenues from ELUNATE®, SULANDA® and the potential upcoming approval of savolitinib, likely to be a first-in-class selective c-MET inhibitor in China.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Surufatinib

            Therapeutic Area: Oncology Product Name: Sulanda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 30, 2020

            Details:

            The NMPA approval of Sulanda® was based on results from the SANET-ep study. The Phase III SANET-ep trial demonstrated surufatinib reduced risk of progressio